No abstract

M inimal hepatic encephalopathy (MHE) is a prevalent neurocognitive complication of cirrhosis that is diagnosed in up to 80% of patients with cirrhosis. It is associated with increased progression to overt hepatic encephalopathy (OHE) and impaired driving skills. 1-3 MHE patients have impaired attention, visuomotor coordination, psychomotor speed, and response inhibition. 4 Paper-pencil standard psychometric tests (SPT) or the computerized inhibitory control test (ICT) can be used to diagnose MHE. 5

PPI therapy is associated with SBP in patients with advanced cirrhosis. Prospective studies are needed to determine whether PPI avoidance can reduce the incidence of SBP and improve outcomes.

Background & Aims-In patients with cirrhosis, hepatic encephalopathy (HE) has acute but reversible as well as chronic components. We investigated the extent of residual cognitive impairment following clinical resolution of overt HE (OHE).

Cirrhotics with CDAD have a higher mortality, LOS, and charges on the NIS 2005 compared with those without CDAD. Antibiotic and PPI use are risk factors for CDAD development in hospitalized cirrhotics.